Fang, M., Luo, T., Ji, Y., Zeng, J. (2025). Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8063